Olesen K H, Andersen J D, Rygg I
Life Support Syst. 1983 Oct-Dec;1(4):247-53.
Forty-four patients with mitral and/or aortic Lillehei-Kaster valvular prostheses were evaluated with regard to haemolysis, hyposideraemia and anaemia, with median intervals of 0.4 years and 7.0 years after the operation. At the first study the majority of patients presented slight to moderate haemolysis; 7 per cent showed hyposideraemia, while none had overt anaemia. At the long-term follow-up the incidence and degree of haemolysis had increased slightly; hyposideraemia was present in 16 per cent, while only one patient had developed anaemia. The modest increase of haemolysis could be accounted for, at least in part, by the development of paravalvular regurgitation or additional valvular disease. It is concluded that the Lillehei-Kaster prostheses are less traumatic to the red cells than earlier types of synthetic prostheses. Apparently, iron medication is indicated only in the minority of patients who develop hyposideraemia and a low normal or decreased haemoglobin value.
对44例植入Lillehei-Kaster二尖瓣和/或主动脉瓣人工瓣膜的患者进行了溶血、低铁血症和贫血评估,术后中位间隔时间分别为0.4年和7.0年。在首次研究时,大多数患者出现轻度至中度溶血;7%的患者出现低铁血症,而无一例有明显贫血。在长期随访中,溶血的发生率和程度略有增加;16%的患者出现低铁血症,只有1例患者发生贫血。溶血的适度增加至少部分可归因于瓣周反流或其他瓣膜疾病的发展。得出的结论是,Lillehei-Kaster人工瓣膜对红细胞的损伤比早期类型的合成人工瓣膜小。显然,仅在少数出现低铁血症且血红蛋白值略低于正常或降低的患者中才需要使用铁剂治疗。